Company profile
CalciMedica, Inc.
NASDAQ:CALCBiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03709342 | phase2 | completed | 2019-01-06 | 2019-03-07 | CalciMedica, Inc. | A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis |
| NCT05171920 | phase2 | withdrawn | 2022-01-24 | 2022-07-01 | CalciMedica, Inc. | A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia |
| NCT06374797 | phase2 | terminated | 2024-07-01 | 2026-04-06 | CalciMedica, Inc. | A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" |
| NCT04681066 | phase2 | completed | 2021-03-24 | 2024-05-15 | CalciMedica, Inc. | A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS |
| NCT04661540 | phase2 | terminated | 2021-03-02 | 2021-12-21 | CalciMedica, Inc. | A Study of Auxora in Patients With Critical COVID-19 Pneumonia |
FDA applications (0)
No records yet.